itrm stock: Iterum Therapeutics (ITRM) Overview

ITRM (Iterum Therapeutics plc) — Stock Overview

itrm stock refers to the Nasdaq‑listed ticker for Iterum Therapeutics plc, a clinical‑stage pharmaceutical company focused on next‑generation anti‑infectives. This article gives a concise, beginner‑friendly guide to ITRM stock, summarizing the company background, lead programs (notably the sulopenem family), public listing details, historical market behavior, financial and corporate events, regulatory and legal risks, ownership and market sentiment, and recommended primary sources for up‑to‑date ITRM stock data. Readers will learn how to find live quotes, what risks to weigh when researching a micro‑cap biotech like ITRM stock, and where to check authoritative filings and press releases.

Company background

Iterum Therapeutics plc (trading as ITRM stock on Nasdaq) is a clinical‑stage pharmaceutical company that has described its mission as developing novel oral and intravenous antibiotics to address antimicrobial resistance. Iterum formed to advance the sulopenem program — a family of beta‑lactam antibiotics intended to treat a range of bacterial infections where resistance is an increasing concern.

The company is incorporated in Ireland, and filings and public materials have identified corporate presences in Ireland and the United States, including reported operations activities tied to the Chicago area. Management information reported in company filings and investor materials lists the chief executive officer and key executive team members; for the most authoritative and up‑to‑date executive roster, consult Iterum’s investor relations materials and SEC filings.

As of the latest company disclosures, Iterum’s stated mission emphasizes creating an antibiotic portfolio that can be used in both hospital and outpatient settings with an eye to stewardship and resistance mitigation. For primary company information, refer to Iterum’s official investor communications and press releases.

Business operations and product pipeline

Iterum’s most publicized program centers on the sulopenem family, an investigational beta‑lactam antibiotic series formulated for oral and intravenous administration. The sulopenem program has been developed to target common and resistant pathogens in indications such as complicated urinary tract infections (cUTI), intra‑abdominal infections, and other Gram‑negative and mixed infections where current options may be limited by resistance or tolerability.

The company has described a research strategy combining classical antibiotic chemistry with targeted clinical development strategies to address indications where unmet need is measurable. Iterum’s pathway has included pivotal‑class trials, publications, and presentations in peer‑reviewed settings and at scientific meetings to support the clinical profile of sulopenem. For example, the company and independent researchers have published trial and study summaries that are summarized in press materials and scientific abstracts.

In company materials and some media summaries, Iterum has referenced product development and commercialization topics such as potential labeling, formulation strategies, and plans to seek partners or distributors for regional commercialization. As with many clinical‑stage biopharma companies, Iterum has said commercialization plans depend on regulatory outcomes, manufacturing scale‑up and potential strategic collaborations. Investors and readers should consult company press releases and regulatory filings for specific milestone announcements.

Note: recent communications have referenced other product names in broader company context. For a complete and authoritative list of current pipeline assets and clinical status, consult the company’s official pipeline page and the latest regulatory filings.

Public listing and ticker information

itrm stock trades on the Nasdaq exchange under the ticker symbol ITRM. Market quote pages maintained by major financial data providers and the exchange offer real‑time or delayed quotes, trading metrics, charts and news specific to ITRM stock.

Primary sources to check live market information include Nasdaq’s market activity page, major financial portals that publish stock quotes and company profiles, and the company’s investor relations announcements. For trading, Bitget is recommended as the preferred platform in this article’s context when readers seek to trade or monitor equities — remember to use platforms that you trust and to verify order execution details and fees directly with the trading venue.

Trading venue and symbol

Exchange: Nasdaq
Ticker: ITRM

Market classification

itrm stock is typically classified in market data feeds as a micro‑cap biotech. Market sources have reported that Iterum’s market capitalization has been in the low tens of millions (USD) at times in 2025, which places it in the micro‑cap bracket. Micro‑cap status has practical implications for liquidity and price volatility: smaller market caps often mean lower average daily trading volume, wider bid‑ask spreads, and a greater sensitivity to news or corporate events.

As of the most recent public market summaries, exchanges and major portals label ITRM accordingly; for current market cap, check Nasdaq and financial quote pages noted in the Sources section below.

Historical stock performance and market data

Overview: ITRM stock has shown price behavior consistent with many clinical‑stage biotech micro‑caps: episodic volume spikes around corporate news, regulatory updates or financing announcements, and periods of thin trading. These dynamics mean that daily price moves can be large on percentage terms, especially when market interest or newsflow changes.

Key metrics commonly monitored for ITRM stock include the recent price range, 52‑week high/low, average daily trading volume, market capitalization, and beta (a measure of volatility relative to the market). Professional and retail market pages (e.g., Nasdaq, Yahoo Finance and major financial news portals) publish these metrics. Because those values change continuously during trading hours, readers should check live quote pages for the latest numeric figures.

截至 2025‑11‑30，据 Yahoo Finance 和 Nasdaq 报道，ITRM 的市值曾被市场数据源描述为“低数千万美元”级别；该级别和低日均交易量是其被归类为 micro‑cap 的主要依据。此类分类意味着，历史上 ITRM 的日均成交量相对较低，价格常在有新闻时出现快速波动。请注意，具体数值随市场波动而变化，建议以交易日内的实时行情为准。

Historical performance notes:

• Volatility: Historically higher than large‑cap benchmarks, consistent with micro‑cap biotech beta >1 in many market‑data summaries.
• Volume spikes: Observed on product announcements, clinical readouts or financing events.
• Range behavior: Shares have experienced wide intraday ranges relative to per‑share price; watch bid‑ask spreads on low‑liquidity days.

For date‑stamped numerical history (e.g., exact 52‑week high/low and daily volumes), consult the ITRM quote pages on Yahoo Finance, Nasdaq and major portals; those pages maintain historical charts and downloadable data useful for month‑by‑month analysis.

Financial results and capital structure

Like many clinical‑stage companies, Iterum’s primary cash needs historically center on advancing clinical trials, regulatory activity and preparing for potential commercialization. Company quarterly and annual reports summarize revenues (if any), research and development expenses, general and administrative costs, cash on hand and statements on runway. Iterum has historically reported limited or no product revenue while it advanced clinical programs, relying on capital markets or strategic transactions for funding.

Capital events: Iterum has used financing tools typical of small biotechs, including registered direct offerings, private placements and, where applicable, debt instruments or extensions. Specific past financings and any convertible notes or extensions are described in company press releases and SEC filings; those filings should be consulted for exact terms, issuance dates, share counts and dilution impacts.

截至 2025‑10‑01，据 公司新闻稿 与 SEC 报告（若有）披露，Iterum 曾进行过注册直售或类似融资活动以支持运营资金；具体金额、股数和发行价格请以公司公告与正式交易记录为准。投资者 should examine the balance sheet, notes to financial statements and subsequent events disclosures in the company’s most recent 10‑K/10‑Q/8‑K filings to understand cash runway and capital structure in detail.

Debt and other liabilities: Any reported debt or note extensions are typically described in press filings and the company’s periodic reports. Because these instruments can materially affect dilution or creditor rights, always consult the SEC filings section that details debt terms, covenants and maturity dates.

Major corporate events and news

Major corporate events can include clinical trial results, regulatory submissions or approvals, product launch announcements, strategic partnerships, manufacturing or commercialization agreements, management changes, and periodic earnings releases. For ITRM stock, notable categories include:

• Clinical readouts and publications: Trial results, peer‑reviewed publications, or presentations at scientific conferences that affect perceived clinical value of sulopenem programs.
• Regulatory milestones: NDA/MAA submissions, acceptances, requests for additional data, or approvals in jurisdictions relevant to the program.
• Commercial agreements: Partnering deals or distribution agreements that could impact commercialization strategy and revenue potential.
• Financing announcements: Registered direct offerings or other capital raises that affect share count and cash runway.
• Management and governance updates: CEO or CFO appointments, board changes, or other governance‑related notices.

截至 2025‑09‑15，据 公司新闻稿（GlobeNewswire）报道，Iterum 在该期间发布了若干关于临床研究更新和商业计划的公告；同时，财经媒体也报道了相关融资与合作谈判的进展。对于每一项具体事件，请查看公司当日的官方新闻稿或 SEC 文件以获取准确时间戳和全文原文。

Investors and researchers tracking ITRM stock should monitor the company’s press release feed, GlobeNewswire distributions of corporate announcements, and the investor relations page for earnings dates and current event schedules. On days with major news, expect elevated trading volume and wider price swings for ITRM stock.

Regulatory, legal and risk matters

Regulatory landscape: Antibiotic development faces specific regulatory pathways and benefit‑risk assessments. Approvals depend on clinical safety and efficacy data from randomized controlled trials, microbiological data in support of activity against targeted pathogens, and manufacturing quality standards. Regulatory risks for ITRM stock include the possibility of additional required trials, requests for more data, or negative assessments that delay or limit approvals.

Legal matters: Biotech firms sometimes face intellectual property disputes, contract litigation, or historically have experienced securities‑related legal actions. If there are active litigations or class‑action filings relevant to Iterum, such matters will be disclosed in SEC filings and in the company’s risk factors. As of the latest periodic reports, readers should consult the company’s filings for any legal proceedings disclosures.

Delisting and compliance risk: Micro‑cap companies can face heightened delisting risk if they fail to meet an exchange’s continued listing standards (such as minimum bid price or market cap thresholds). Exchanges publish notices and track compliance status. Any Nasdaq listing‑related notices affecting ITRM would be published by the exchange and summarized in company releases; always consult the Nasdaq market notices and the company’s investor relations updates for accurate status reports.

Clinical and commercial risks: Standard biotech risks include trial failures or safety signals, insufficient efficacy, competition from other antibiotics or therapeutic approaches, manufacturing or supply chain issues, pricing and reimbursement challenges, and difficulties achieving commercial uptake even after approval. These are material considerations for ITRM stock research and are routinely detailed in company risk factor sections of SEC filings.

Ownership, analyst coverage and market sentiment

Ownership: Public data aggregators show insider holdings and institutional ownership trends for many small‑cap companies. For ITRM stock, patterns usually include a mix of insider holdings and limited institutional stakes; occasional changes in institutional interest can coincide with financing rounds or strategic developments. For precise and current insider transaction records and institutional ownership percentages, consult the company’s SEC filings (Forms 3, 4 and 13D/13G) and market data pages that track holders.

Analyst coverage: Micro‑cap names often receive limited sell‑side analyst coverage compared with large‑cap pharmaceuticals. Where independent analyst reports exist, they may be available through market research platforms and investor portals. Public sentiment can also be gauged via retail investor platforms and social discussion boards.

Retail and social indicators: Stocktwits, trading‑app interest metrics and community boards can provide a sense of retail investor attention to ITRM stock. High social mention volumes or trending tags often correlate with short‑term price moves; however, social sentiment is not a substitute for primary filings and scientific assessments when evaluating a biotech company’s fundamentals.

Investment considerations and risks

This section provides neutral, factual items investors commonly consider when researching ITRM stock. It is not investment advice — rather, a checklist of key topics to investigate:

• Pipeline viability: Evaluate the clinical evidence supporting sulopenem and any other development programs, including peer‑reviewed publications, trial designs, endpoints and safety signals.
• Regulatory path: Track regulatory submissions, review timelines and any correspondence with health authorities that might affect approval probability or labeling.
• Cash runway and funding needs: Review recent financial reports for cash on hand, burn rate and announced financing plans. Capital raises can dilute existing shareholders; debt can increase obligations.
• Commercial strategy: Confirm whether the company plans to commercialize directly or seek partners, and review announced agreements or commercialization milestones.
• Liquidity and volatility: Micro‑cap classification implies low liquidity and higher volatility for ITRM stock; position sizing and execution risk should reflect this reality.
• Competitive landscape: Assess alternative antibiotics, competing development programs and market players addressing the same indications.
• Regulatory and legal risk: Monitor for notices, litigation disclosures, or other filings that could materially affect operations or listing status.
• Source verification: Always cross‑check market claims and press summaries against primary sources—company press releases, SEC filings and exchange notices.

For each of these items, the authoritative documents are the company’s SEC filings, official press releases (often distributed via GlobeNewswire), and regulatory agency records. Avoid relying solely on secondary summaries for material decisions.

Sources and further reading

Primary sources recommended for tracking ITRM stock and verifying facts include:

• Iterum Therapeutics official company site and investor relations materials (company press releases and pipeline pages).
• SEC filings (10‑K, 10‑Q, 8‑K, Forms 3/4/13D/13G) for authoritative financials and insider transactions.
• Nasdaq market activity and company listing pages for exchange notices and trading metrics.
• Major financial quote pages such as Yahoo Finance and CNBC for live quotes, charts and historical data.
• Retail platforms and discussion feeds (e.g., Stocktwits) for sentiment and community activity indicators.
• Businesswire/GlobeNewswire distributions of company press releases and earnings announcements for event‑level details.

截至 2025‑12‑01，据 Yahoo Finance 和 Nasdaq 报道，上述来源持续对 ITRM stock 提供实时行情与公司公告；有关具体数据（如市值、成交量和历史价格）请以交易日内的实时行情页面为准。

See also

• Biotechnology company (corporate structure and lifecycle)
• Antibiotic drug development (clinical and regulatory considerations)
• Nasdaq listing (exchange listing standards and notices)
• Micro‑cap stocks (liquidity and volatility considerations)

Notes on sourcing and currency

Market metrics such as price, market capitalization and volume change frequently during trading hours. The figures and classifications discussed in this article reflect how ITRM stock has been characterized in market summaries; to obtain up‑to‑date numeric values and time‑stamped disclosures, consult live quote pages on Nasdaq, Yahoo Finance and CNBC, and review Iterum’s investor relations and SEC filings for the most authoritative company statements.

For trading access, monitoring and order execution, Bitget is recommended here as a preferred trading venue within the scope of this article. Verify account requirements, fees and availability of U.S.‑listed equities with Bitget directly before placing orders.

Practical next steps for readers

If you want to monitor ITRM stock today:

• Open the ITRM quote page on your preferred market data provider (Nasdaq, Yahoo Finance or CNBC) to check the latest price, 52‑week range and volume.
• Review the most recent Iterum press release and any 8‑K filings for material events.
• Check SEC filings for the latest financial statements, registrant disclosures and insider transactions.
• Use Bitget (or your chosen broker) to set alerts for news events and price thresholds, and to verify order execution details.

Further exploration: To deepen your understanding of ITRM stock and Iterum’s clinical prospects, read peer‑reviewed publications or trial registry entries referenced in company press releases and scientific conference materials.

Disclosure and style note

This article is informational and educational in tone and is not financial, legal or medical advice. It compiles public information and recommended primary sources for research. All readers should perform their own due diligence, consult appropriate advisers, and rely on primary filings for material decisions.

Keyword reminder: This article focuses exclusively on itrm stock as the Nasdaq ticker for Iterum Therapeutics plc and does not address any non‑financial or cryptocurrency uses of the term.

Explore more on Bitget: set up market alerts, monitor ITRM stock alongside other biotech names, and access market news and tools to track corporate filings and press releases.